327 related articles for article (PubMed ID: 24722313)
1. Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation.
Kickingereder P; Sahm F; Wiestler B; Roethke M; Heiland S; Schlemmer HP; Wick W; von Deimling A; Bendszus M; Radbruch A
AJNR Am J Neuroradiol; 2014 Aug; 35(8):1503-8. PubMed ID: 24722313
[TBL] [Abstract][Full Text] [Related]
2. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
[TBL] [Abstract][Full Text] [Related]
4. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma.
Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS
AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384
[TBL] [Abstract][Full Text] [Related]
5. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
[TBL] [Abstract][Full Text] [Related]
7. The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival.
Choi YS; Kim DW; Lee SK; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Ahn SS
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2235-41. PubMed ID: 26338911
[TBL] [Abstract][Full Text] [Related]
8. Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI.
Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
Clin Radiol; 2015 Dec; 70(12):1393-9. PubMed ID: 26382744
[TBL] [Abstract][Full Text] [Related]
9. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
10. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging.
Xi YB; Kang XW; Wang N; Liu TT; Zhu YQ; Cheng G; Wang K; Li C; Guo F; Yin H
Eur J Radiol; 2019 Mar; 112():59-64. PubMed ID: 30777220
[TBL] [Abstract][Full Text] [Related]
12. Glioma: Application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading.
Jung SC; Yeom JA; Kim JH; Ryoo I; Kim SC; Shin H; Lee AL; Yun TJ; Park CK; Sohn CH; Park SH; Choi SH
AJNR Am J Neuroradiol; 2014 Jun; 35(6):1103-10. PubMed ID: 24384119
[TBL] [Abstract][Full Text] [Related]
13. Mitotic Activity in Glioblastoma Correlates with Estimated Extravascular Extracellular Space Derived from Dynamic Contrast-Enhanced MR Imaging.
Mills SJ; du Plessis D; Pal P; Thompson G; Buonacorrsi G; Soh C; Parker GJ; Jackson A
AJNR Am J Neuroradiol; 2016 May; 37(5):811-7. PubMed ID: 26705318
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma and primary central nervous system lymphoma: Preoperative differentiation by using MRI-based 3D texture analysis.
Xiao DD; Yan PF; Wang YX; Osman MS; Zhao HY
Clin Neurol Neurosurg; 2018 Oct; 173():84-90. PubMed ID: 30092408
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction.
Toh CH; Wei KC; Chang CN; Ng SH; Wong HF
AJNR Am J Neuroradiol; 2013; 34(6):1145-9. PubMed ID: 23348763
[TBL] [Abstract][Full Text] [Related]
16. T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status.
Arevalo-Perez J; Thomas AA; Kaley T; Lyo J; Peck KK; Holodny AI; Mellinghoff IK; Shi W; Zhang Z; Young RJ
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2256-61. PubMed ID: 26338913
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.
Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH
Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Diagnostic Accuracy of DSC- and Dynamic Contrast-Enhanced MRI in the Preoperative Grading of Astrocytomas.
Nguyen TB; Cron GO; Perdrizet K; Bezzina K; Torres CH; Chakraborty S; Woulfe J; Jansen GH; Sinclair J; Thornhill RE; Foottit C; Zanette B; Cameron IG
AJNR Am J Neuroradiol; 2015 Nov; 36(11):2017-22. PubMed ID: 26228886
[TBL] [Abstract][Full Text] [Related]
19. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
[TBL] [Abstract][Full Text] [Related]
20. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ
J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
